Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $81.08 | Prev. Close $81.08 | Circuit Range N/A |
Day Range $81.08 - $84.36 | Year Range $16.25 - $103.77 | Volume 2,156 |
Average Traded $82.95 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $81.08 | $84.36 | +0.00% |
12-Nov-25 | $81.08 | $84.36 | +0.49% |
11-Nov-25 | $81.49 | $83.95 | +1.29% |
10-Nov-25 | $83.06 | $82.88 | +1.93% |
07-Nov-25 | $78.13 | $81.31 | -1.20% |
06-Nov-25 | $81.37 | $82.30 | -0.89% |
05-Nov-25 | $81.50 | $83.03 | +0.04% |